Key result
Thrombolysis in STEMI is linked to ~81% greater likelihood of improved 12-month NYHA class.
Why the study?
Data comparing clinical outcomes, particularly morbidity and mortality, between thrombolyzed and non-thrombolyzed STEMI patients in the Indian population are limited.
Does thrombolytic therapy improve morbidity and mortality in STEMI patients compared to non-thrombolyzed patients?
Observational (n=70)
No
Does thrombolytic therapy improve morbidity and mortality in STEMI patients compared to non-thrombolyzed patients?
Absolute Event Rate: 25% vs 13.8%
p-value: p=<0.005
Thrombolytic therapy combined with revascularization may improve effort tolerance and reduce anginal pain compared to revascularization alone in STEMI patients.
Thrombolysis may associate with better effort tolerance in STEMI; leaves open effects on mortality and requires randomized confirmation before practice change.
Background: There is a paucity of data that compare clinical outcomes, especially morbidity and mortality among thrombolyzed and non-thrombolyzed ST-segment elevation myocardial infarction (STEMI) patients in Indian population.Methods: An observational, single-centre study involving 70 patients who were diagnosed with STEMI from February 2014 to June 2015. Patients were thrombolysed after meticulous evaluation of indications for thrombolytic therapy, and later whenever needed they were subjected to revascularization therapy of either percutenous coronary intervention (PCI) or coronary artery bypass graft (CABG). Then, STEMI patients were categorized into thrombolyzed and non-thrombolyzed groups. Mortality and morbidity parameters such as effort tolerance expressed in terms of New York Heart Association (NYHA) functional class and typical anginal chest pain at 1, 6, and 12-month were primary outcomes.Results: Mean age of the cohort was 53.2 years: 48 men and 22 women. Of the total, 58 (82.9%) patients underwent thrombolysis. Mean window period of thrombolysis therapy was 8.1±2.0 hours. Revascularization was required in 80% of cases. At 12-month, STEMI patients who were thrombolyzed had significantly better effort tolerance in terms of NYHA class than those who were non-thrombolyzed (25% versus 13.8%; p<0.005). At 1 and 6-month, STEMI patients who were thrombolyzed had significantly better effort tolerance in terms of typical anginal pain than those who were non-thrombolyzed (1-month, 82.8% versus 58.3%; p<0.005; 6-month, 4.3% versus 0.0%; p<0.005).Conclusions: This study enlightened the effectiveness of thrombolytic therapy together with revascularization (CABG or PCI) in reducing the morbidity rate than revascularization alone.
No takes yet. Share an insight, caveat, or question.
Kadloor et al. (2022) conducted an observational in ST-segment elevation myocardial infarction (STEMI) (n=70). Thrombolytic therapy vs. Non-thrombolyzed was evaluated on Effort tolerance (NYHA class) at 12 months (p=<0.005). Thrombolytic therapy in STEMI patients was associated with significantly better effort tolerance in terms of NYHA class at 12 months compared to non-thrombolyzed patients (25% vs 13.8%).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: